The Four Key Areas Propelling This Defense Stock Higher

Michael A. Robinson

When we spoke on Dec. 26, I suggested you invest in United Technologies Corp. (NYSE: UTX).

At the time, I noted the sprawling defense and industrials firm had completed a $23 billion buyout of aerospace supplier Rockwell Collins.

I went on to say that United Technologies provides access to a very lucrative field of investing – corporate spin-offs. This one gives shareholders access to three separate stocks.

But today I'm writing to let you know I now have placed the stock on hold. Rest assured this was not an easy decision.

After all, I still believe in the company's long-term growth.

It's the short term that is the problem, now that the firm has announced an all-stock deal to merge with Raytheon Co. (NYSE: RTN) to create a defense giant with $74 billion in sales.

So today I'm going to walk you through the reasons I have the stock on hold.

And I'll also show you a lucrative defense pick that is putting the market to complete shame…

Why Long-haul Spin-offs Can Pay

If you have followed along with me for any length of time, then you know I'm a big fan of corporate spin-offs. Slimming down a big company often greatly improves efficiencies and profit margins.

It's also good for shareholders. Two professors at Penn State University examined 30 years of market data covering 174 spin-offs.

Their study revealed that in the first three years of operations, these new companies showed price appreciations of 76%, beating the S&P 500 by 31%.

Must See: The South China Sea is about to get violent. But thanks to a small $6 U.S. defense firm with a top-secret new technology, China is about to be taken to the woodshed. Read more…

That's backed up by Lehman Bros., which studied 85 spin-offs between 2000 and 2005. The firm found that they beat the S&P 500 by as much as 45% in their first two years as independent companies.

In the case of UTX, investors get access to three stocks for the price of one. After it completed the merger with Rockwell Collins last November, United Technologies said it would spin off its Otis elevator and Carrier building systems units into separate firms.

Otis has more than $12 billion in yearly sales, much of that in the form of recurring revenues. It produces more than $2 billion in adjusted earnings each year.

And the Carrier segment is a global leader in heating, ventilation, and air-conditioning (HVAC). It has around $18 billion in yearly sales and is quite profitable. Last year, it brought in roughly $3.5 billion in adjusted earnings.

So, I'm still a big believer in the value of the spin-off. I think it will pay off well… over the long haul.

Short-term Issues

But the company's decision to merge with Raytheon casts too much short-term doubt on the stock.

Before I go into those details, let me explain what I mean by a "hold" on UTX.

Literally, I'm saying that if you own it already, I would not sell unless for some reason it triggers your protective stop. The main thing is not to wade in now, no matter what you hear from Wall Street.

I have three main reasons for saying this:

1. The complex move to bulk up and spin off at the same time could distract management until it's all complete in the first half of next year.
2. President Trump has already voiced concerns that the combined firm might limit competition at a time when Capitol Hill also is worried about corporate size.
3. Activist investor Bill Ackman has come out strongly against the deal. His Pershing Square Capital Management hedge fund owns more than $700 million in UTX stock and is likely to seek help from other investors in trying to block the deal.

If I had to guess, based on what I know about the defense industry and the need to deliver more platforms with greater efficiency, I'd say the merger will ultimately go through.

However, UTX is asking investors to wait at least six months and maybe a year before we know how all this shakes out.

That's a long time for shareholders to circle the wagons. And there's no reason to do that.

Not when we can instead put our hard-earned money into this stock.

This Defense Stock Is on the Cutting Edge of Tech

Michael A. Robinson

About the Author

Browse Michael's articles | View Michael's research services

Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...

• He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
• He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
• As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.

This all means the entire world is constantly seeking Michael's insight.

In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.

Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.

And even with decades of experience, Michael believes there has never been a moment in time quite like this.

Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.

To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.

His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.

… Read full bio